The short answer
Most wealthy countries negotiate drug prices nationally: a single body evaluates a new drug's benefit and sets or negotiates a price for the whole country. The U.S., for most of its history, did not — each insurer negotiates separately, Medicare was long barred from negotiating at all, and manufacturers can largely set launch prices freely. Fragmented buyers plus free pricing equals higher prices.
The longer answer: five structural drivers
1. No national price negotiation (until recently)
The Inflation Reduction Act changed this for the first time: Medicare now negotiates prices for a growing list of top-spending drugs, with the first negotiated prices taking effect in 2026, and manufacturers owe rebates if prices rise faster than inflation. It's a genuine shift, but it covers a limited set of drugs.
2. Patent strategies extend monopolies
"Evergreening" — layering secondary patents on formulations, delivery devices, and manufacturing tweaks — can extend effective exclusivity years past the original patent, delaying generic competition on some of the biggest-selling drugs.
3. The middle of the supply chain is opaque
Pharmacy benefit managers (PBMs) negotiate rebates from manufacturers in exchange for formulary placement. Rebates are calculated off the list price, which creates pressure to keep list prices high — and patients' cost-sharing is often based on that inflated list price, not the net price after rebates.
4. Insurance design shifts costs to the sick
Deductibles and coinsurance mean the people who use the most medication pay the most out of pocket — the opposite of how insurance is supposed to work. This is why the same drug can "cost" $10 or $600 depending on the month and the plan.
5. Little price transparency
Until recently, almost no one — not patients, often not doctors — could see what a drug would actually cost at the counter. That's improving with price-comparison tools and real-time benefit checks, but the default is still opacity.
The important nuance: generics are a US success story
Here's the part that surprises people: U.S. generic prices are among the lowest in the world. About 90% of U.S. prescriptions are filled generically, and fierce competition keeps most generics very cheap. The affordability crisis is concentrated in brand-name and specialty drugs. Practically, this means the fastest personal fix is maximizing your use of generics and the programs in our savings guide.
What's changing right now
- Medicare negotiation — first negotiated prices effective 2026, with more drugs added each year.
- $2,000 annual cap on Medicare Part D out-of-pocket costs (from 2025), plus the $35/month insulin cap.
- Biosimilars — competition for expensive biologics (like insulin and autoimmune drugs) is finally arriving and has already cut some list prices dramatically.
- Transparent-pricing pharmacies — cost-plus models publish their markup, pressuring the rest of the market.
- State importation programs — the FDA authorized Florida's program to import certain drugs from Canada at the state level in 2024; implementation has been slow and contested, and it does not change the rules for individuals.
What you can actually control
You can't fix the system, but you can refuse to pay list price. The three highest-yield moves: fill generic wherever clinically appropriate, compare cash prices before every new fill, and claim every assistance program you qualify for. Our step-by-step savings playbook covers all three.